Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial
The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this pha...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13330 |
| _version_ | 1811161234607702016 |
|---|---|
| author | Henrik Horndalsveen Tine Norman Alver Astrid Marie Dalsgaard Lotte Victoria Rogg Nina Helbekkmo Bjørn Henning Grønberg Tarje Onsøien Halvorsen Christina Ramberg Vilde Drageset Haakensen Åsa Kristina Öjlert Maria Moksnes Bjaanæs Åslaug Helland |
| author_facet | Henrik Horndalsveen Tine Norman Alver Astrid Marie Dalsgaard Lotte Victoria Rogg Nina Helbekkmo Bjørn Henning Grønberg Tarje Onsøien Halvorsen Christina Ramberg Vilde Drageset Haakensen Åsa Kristina Öjlert Maria Moksnes Bjaanæs Åslaug Helland |
| author_sort | Henrik Horndalsveen |
| collection | DOAJ |
| description | The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in patients (n = 21) with advanced non‐small‐cell lung cancer treated with atezolizumab and stereotactic body radiotherapy in the second or later line. We found the combined treatment to be safe with grade 3 toxicity reported in three patients. As the best overall response, four patients had a partial response, eight had stable disease and five had progressive disease. Median overall survival time was still not reached after a median follow‐up of 26.5 months and 10/15 patients with programmed death‐ligand 1 negative tumours were alive >18 months after the start of the study treatment. ctDNA was detectable at baseline in 11 patients. A rapid decline in ctDNA to <30% of baseline levels was seen in three patients, two of which were radiographic responders and one was considered clinically benefiting from therapy for almost 1 year. |
| first_indexed | 2024-04-10T06:11:04Z |
| format | Article |
| id | doaj.art-c6d28e0b01ad441e9b373dc142c71765 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-04-10T06:11:04Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-c6d28e0b01ad441e9b373dc142c717652023-03-02T15:43:22ZengWileyMolecular Oncology1574-78911878-02612023-03-0117348749810.1002/1878-0261.13330Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trialHenrik Horndalsveen0Tine Norman Alver1Astrid Marie Dalsgaard2Lotte Victoria Rogg3Nina Helbekkmo4Bjørn Henning Grønberg5Tarje Onsøien Halvorsen6Christina Ramberg7Vilde Drageset Haakensen8Åsa Kristina Öjlert9Maria Moksnes Bjaanæs10Åslaug Helland11Department of Oncology Oslo University Hospital NorwayDepartment of Cancer Genetics, Institute for Cancer Research Oslo University Hospital NorwayDepartment of Cancer Genetics, Institute for Cancer Research Oslo University Hospital NorwayDepartment of Oncology Oslo University Hospital NorwayDepartment of Pulmonology University Hospital of North Norway Tromsø NorwayDepartment of Clinical and Molecular Medicine NTNU, Norwegian University of Science and Technology Trondheim NorwayDepartment of Clinical and Molecular Medicine NTNU, Norwegian University of Science and Technology Trondheim NorwayDepartment of Medical Physics Oslo University Hospital NorwayDepartment of Oncology Oslo University Hospital NorwayDepartment of Oncology Oslo University Hospital NorwayDepartment of Oncology Oslo University Hospital NorwayDepartment of Oncology Oslo University Hospital NorwayThe introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non‐small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in patients (n = 21) with advanced non‐small‐cell lung cancer treated with atezolizumab and stereotactic body radiotherapy in the second or later line. We found the combined treatment to be safe with grade 3 toxicity reported in three patients. As the best overall response, four patients had a partial response, eight had stable disease and five had progressive disease. Median overall survival time was still not reached after a median follow‐up of 26.5 months and 10/15 patients with programmed death‐ligand 1 negative tumours were alive >18 months after the start of the study treatment. ctDNA was detectable at baseline in 11 patients. A rapid decline in ctDNA to <30% of baseline levels was seen in three patients, two of which were radiographic responders and one was considered clinically benefiting from therapy for almost 1 year.https://doi.org/10.1002/1878-0261.13330circulating tumour DNAimmunotherapyliquid biopsyNSCLCradiotherapy |
| spellingShingle | Henrik Horndalsveen Tine Norman Alver Astrid Marie Dalsgaard Lotte Victoria Rogg Nina Helbekkmo Bjørn Henning Grønberg Tarje Onsøien Halvorsen Christina Ramberg Vilde Drageset Haakensen Åsa Kristina Öjlert Maria Moksnes Bjaanæs Åslaug Helland Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial Molecular Oncology circulating tumour DNA immunotherapy liquid biopsy NSCLC radiotherapy |
| title | Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial |
| title_full | Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial |
| title_fullStr | Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial |
| title_full_unstemmed | Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial |
| title_short | Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial |
| title_sort | atezolizumab and stereotactic body radiotherapy in patients with advanced non small cell lung cancer safety clinical activity and ctdna responses the comit 1 trial |
| topic | circulating tumour DNA immunotherapy liquid biopsy NSCLC radiotherapy |
| url | https://doi.org/10.1002/1878-0261.13330 |
| work_keys_str_mv | AT henrikhorndalsveen atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT tinenormanalver atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT astridmariedalsgaard atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT lottevictoriarogg atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT ninahelbekkmo atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT bjørnhenninggrønberg atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT tarjeonsøienhalvorsen atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT christinaramberg atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT vildedragesethaakensen atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT asakristinaojlert atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT mariamoksnesbjaanæs atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial AT aslaughelland atezolizumabandstereotacticbodyradiotherapyinpatientswithadvancednonsmallcelllungcancersafetyclinicalactivityandctdnaresponsesthecomit1trial |